bluuebunny/crossref_metadata_2025_split huggingface dataset:
1195-P: Effect of Dapagliflozin on Obstructive Sleep Apnea in Patients with Type 2 Diabetes: A Randomized Controlled Trial
Authors: SUN QIN , TANG YI , ZHANG MIN 
Published: June 2019

Background: Obstructive sleep apnea hypopnea syndrome (OSAHS) is closely correlated to obesity and T2DM. Lose weight is helpful for OSAHS patients. Dapagliflozin, a new hypoglycemic drug, was found to reduce weight of T2DM patients, just like metformin. Therefore, they might have potential therapeutic effects on OSAHS patients with T2DM. Aim: A randomized controlled trial was designed to observe the effects of dapagliflozin combined with metformin on body mass index (BMI), and the ventilation and sleep quality of patients with OSAHS combined with T2DM, as well as some metabolic indicators.
Methods: 36 enrolled OSAHS patients with newly-diagnosed T2DM were randomly assigned to two groups (dapagliflozin group and control group). These patients in dapagliflozin group were given dapagliflozin and metformin for 24 weeks, while controls were given glimepiride and metformin for 24 weeks. apnea-hypopnea index (AHI), minimum oxygen saturation (LSpO2), Epworth somnolence scale (ESS) score and some metabolic indicators were measured before and at 24 weeks after the initiation of treatment.
Results and Conclusion: Our study indicate that dapagliflozin can significantly reduce glucose, BMI, blood pressure and AHI, and improve hypoxemia during sleep and excessive daytime sleepiness (Table 1), which thereby has potential as an effective treatment approach for OSAHS.

Disclosure
Q. Sun: None. Y. Tang: None. M. Zhang: None.
121-OR: Insulin Clearance Is an Independent Determinant of ß-Cell Cell Function in Obese Youths
Authors: GALDERISI ALFONSO , TRICO DOMENICO , GIANNINI COSIMO , SANTORO NICOLA , CAPRIO SONIA , WEISS RAM 
Published: June 2019

Background: Hyperinsulinemia results from β-cell ompensatory adaptation to insulin resistance and reduced insulin clearance. We examined the relationship between hepatic/peripheral insulin clearance and β-cell function in lean and obese insulin sensitive (IS) and insulin resistant (IR) adolescents.
Methods: A 2-step euglycemic hyperinsulinemic clamp and an hyperglycemic clamp were performed in 153 youths (73F, 14.4±3.3y) to evaluate hepatic (MCR1) and peripheral (MCR2) insulin clearance, β-cell function (DIcpep) and insulin sensitivity. Participants were grouped as:non-Obese NGT (nOb-NGT, n=23), obese NGT-IS (Ob-NGT-IS, n=47), obese NGT-IR (Ob-NGT-IR, n=47), and obese IGT (Ob-IGT, n=36). IS and IR were defined according to the median M (glucose disposal) from euglycemic clamp. Effect of MCR1-2, sex, age, BMI, Tanner stage, fasting/2h-glucose, ethnicity on DIcpepwas estimated by multivariate regression model.
Results: IS, MCR1/MCR2 did not differ between nOb-NGT and Ob-NGT-IS. MCR1 was lower in Ob-NGT-IR and Ob-IGT than nOb-NGT, while MCR2 only declined in the Ob-IGT. (upper panels) MCR1 and MCR2 were the sole determinants of DIcpep (p0.006 and p0.015), as confirmed by ~50% reduction in DIcpep of the lowest tertiles of MCR1 and MCR2. (lower panels).
Conclusion: In obese adolescents, lower MCR1 and MCR2 are independently associated with a blunted β-cell function thus playing a key role in youth onset T2D.

Disclosure
A. Galderisi: None. D. Trico: None. C. Giannini: None. N. Santoro: None. S. Caprio: None. R. Weiss: Consultant; Self; Medtronic MiniMed, Inc.

Funding
National Institutes of Health (R01DK085577-01, R01HD40787, R01HD28016, P30DK045735, K12DK094714-02, R01DK111038-01A1); Robert E. Leet and Clara Guthrie Patterson Trust; European Medical International Framework (EMIF115372)
1212-P: Sotagliflozin Reduces Markers of Arterial Stiffness in T1D: Pooled Analysis from inTandem 1 and inTandem 2 Clinical Trials
Authors: RODBARD HELENA W. , GIACCARI ANDREA , DAVIES MICHAEL J. , SAWHNEY SANGEETA , WANG STELLA , GARG SATISH K. , CARIOU BERTRAND 
Published: June 2019

Cardiovascular (CV) disease is a major cause of mortality in type 1 diabetes (T1D). Elevated blood pressure, including both systolic blood pressure (SBP) and diastolic blood pressure (DBP), and increased arterial stiffness are linked to CV events. While SGLT2 inhibitors have shown positive outcomes pertaining to BP and markers of arterial stiffness and vascular resistance in adults with type 2 diabetes, such effects have not been reported previously in T1D. When added as an adjunct to insulin therapy, sotagliflozin (SOTA), a dual SGLT1 and SGLT2 inhibitor, has previously demonstrated significant SBP reduction vs. placebo in adults with T1D. In this post hoc analysis, several indirect markers of arterial stiffness including pulse pressure (PP), mean arterial pressure (MAP), and double product (DP), were calculated using observed SBP, DBP or pulse rate at 24 weeks using pooled data (n=1,575) from the inTandem 1 and 2 studies. Baseline characteristics were similar among groups. Significant placebo-adjusted reductions were observed at week 24 for SOTA 200 and 400 mg in SBP, DBP, MAP, and DP, and in PP for SOTA 400 mg [Table]. The reductions in BP were not associated with increases in heart rate.
In conclusion, treatment with SOTA in adults with T1D resulted in significant reduction in BP and several markers of arterial stiffness and vascular resistance.

Disclosure
H.W. Rodbard: Advisory Panel; Self; Bayer US, Janssen Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk Inc., Sanofi. Consultant; Spouse/Partner; Eli Lilly and Company. Consultant; Self; Gan & Lee Pharmaceuticals. Research Support; Self; Lexicon Pharmaceuticals, Inc., Novo Nordisk Inc., Sanofi. Speaker's Bureau; Self; Merck & Co., Inc., Novo Nordisk Inc. A. Giaccari: Advisory Panel; Self; Sanofi. Board Member; Self; Novo Nordisk A/S. Speaker's Bureau; Self; Amgen Inc., AstraZeneca, Merck Sharp & Dohme Corp., Sanofi. M.J. Davies: Employee; Self; Lexicon Pharmaceuticals, Inc. S. Sawhney: Stock/Shareholder; Spouse/Partner; AstraZeneca, Gilead Sciences, Inc., GlaxoSmithKline plc., Merck & Co., Inc., Pfizer Inc. S. Wang: Employee; Self; Sanofi US. S.K. Garg: Advisory Panel; Self; Eli Lilly and Company, Roche Pharma, Sanofi-Aventis, Zealand Pharma A/S. Research Support; Self; Eli Lilly and Company, WebMD. B. Cariou: Board Member; Self; Novo Nordisk A/S, Regeneron Pharmaceuticals. Consultant; Self; GENFIT, Sanofi-Aventis. Research Support; Self; Amgen Inc., Pfizer Inc. Speaker's Bureau; Self; Abbott, Akcea Therapeutics, Merck Sharp & Dohme Corp.

Funding
Lexicon Pharmaceuticals, Inc.; Sanofi
1213-P: Assessing the Performance of Cardiovascular Risk Equations in the DECLARE-TIMI 58 Population
Authors: MCEWAN PHILIP , FOOS VOLKER , BENNETT HAYLEY , KARTMAN BERNT , EDMONDS CHRISTOPHER , GAUSE-NILSSON INGRID ANNA 
Published: June 2019

Sodium-glucose co-transporter inhibitors have demonstrated reduced incidence of cardiovascular (CV) events, which cannot be fully explained by effects on HbA1c, body weight or blood pressure. Type 2 diabetes mellitus (T2DM) economic models link treatment-related changes in risk factor levels to long-term incidence of CV events via risk equations (RE). This study assessed the performance of commonly used CV RE in T2DM to the CV outcomes trial DECLARE-TIMI 58. Ten sets of RE were coded in MS-Excel (ADVANCE, ARIC, BRAVO, Framingham, Fremantle, New Zealand CVD, QRisk3, Swedish NDR, UKPDS 68 and 82) to predict annual probabilities of CV events and applied to baseline characteristics and 1-year treatment effects (HbA1c, weight and blood pressure) for dapagliflozin (DAPA) versus placebo (PLA) from DECLARE-TIMI 58. Predicted event rates for myocardial infarction (MI), heart failure (HF) and stroke and the relative risks (RR) associated with DAPA versus PLA were estimated and compared to the closest reported trial outcome. Of the ten sets of RE, seven predicted composite CV outcomes, demanding assumptions to predict risk of individual events; only UKPDS and BRAVO predicted all three events. When comparing trial observations against predictions averaged across RE, correlation was greater for absolute event rates (R2: 0.92) than RRs (R2: 0.42). ARIC, Fremantle and New Zealand RE considerably overpredicted risk of MI and stroke compared to the trial. RE typically underpredicted the effect of DAPA on HF (average predicted RR: 0.89 versus reported hazard ratio 0.73, CI: 0.61 to 0.88) and MI (average predicted RR: 0.93 versus reported hazard ratio 0.89, CI: 0.77 to 1.01). Existing methods of CV risk prediction evaluated in this study did not accurately predict the treatment benefits observed in DECLARE-TIMI 58. The development of DECLARE-TIMI 58-specific risk equations may be required to robustly evaluate the long-term clinical and economic impact of DAPA in T2DM.

Disclosure
P. McEwan: Consultant; Self; AstraZeneca. Employee; Self; Health Economics and Outcomes Research Ltd. V. Foos: Employee; Self; Health Economics and Outcomes Research Ltd., IQVIA. H. Bennett: Consultant; Self; AstraZeneca. Employee; Self; Health Economics and Outcomes Research Ltd. B. Kartman: Employee; Self; AstraZeneca. Stock/Shareholder; Self; AstraZeneca. C. Edmonds: Employee; Self; AstraZeneca. I.A. Gause-Nilsson: Employee; Self; AstraZeneca.

Funding
AstraZeneca
1217-P: The Kidney Effects of the SGLT2 Inhibitors on the Japanese Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease
Authors: KOBAYASHI KAZUO , TOYODA MASAO , HATORI NOBUO , SAKAI HIROYUKI , FURUKI TAKAYUKI , TAMURA KOUICHI , MIYAKAWA MASAAKI 
Published: June 2019

Background: In some large-scale clinical trials, the administration of sodium glucose co-transporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM) has revealed pronounced and consistently beneficial renal outcome. However, it is unclear whether long term SGLT2i administration led to similar results in Japanese T2DM patients. Objective: To elucidate the renal effects of long term SGLT2i administration in Japanese T2DM patients with chronic kidney disease (CKD).
Method: Data from T2DM patients with CKD who were visiting members of Kanagawa Physicians Association and being administered SGLT2i for more than 1 year were used.
Result: We analyzed 753 patients. Six SGLT2i types were used with median administration period of 33.0 months. The mean albumin-to-creatinine ratio (ACR) significantly decreased from 36.0 to 27.5 (mg/gCr, p&lt;0.01). Based on intensity, the mean ACR value significantly decreased from 72.1 to 54.8 in microalbuminuric patients (n=288) and from 625.1 to 414.1 in macroalbuminuric patients (n=58) (p&lt;0.01); however, it did not change in normoalbuminuric patients (n=275). Multiple linear regression analysis revealed that the localized ACR baseline value, change (Δ) in systolic and diastolic BP, and ΔHbA1c were independently correlated with ΔACR; values of these regression coefficients were -0.21, 0.01, 0.01, and 0.08, respectively (p&lt;0.01). The eGFR decreased from 77.5±22.2 to 72.7±22.4 mL/min/1.73 m2 (p&lt;0.01). The localized ACR baseline value, ΔBW, age, baseline eGFR, treatment duration, and baseline diastolic BP were independently correlated with ΔeGFR; the regression coefficients were -1.35, -0.42, -0.24, -0.23,-0.11, and -0.08, respectively (p&lt;0.01).
Conclusion: This study confirmed that the improvement of ACR was also observed in the real world; however, eGFR gradually decreased after long term SGLT2i administration. The relationship between background factors should be further discussed in future.

Disclosure
K. Kobayashi: None. M. Toyoda: Speaker's Bureau; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Eli Lilly and Company, Kyowa Hakko Kirin Co., Ltd., Medtronic Japan Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Inc., Sanofi, Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Limited. N. Hatori: None. H. Sakai: None. T. Furuki: None. K. Tamura: Advisory Panel; Self; AstraZeneca. Research Support; Self; AstraZeneca, Ono Pharmaceutical Co., Ltd. Speaker's Bureau; Self; AstraZeneca, Ono Pharmaceutical Co., Ltd. M. Miyakawa: None.
1239-P: Trend in Total Payment and Out-of-Pocket Payment on a Yearly Supply of Oral Antidiabetic Drug Types among U.S. Adults with Private Health Insurance from 2003 to 2016
Authors: SHAO HUI , LAXY MICHAEL , BENOIT STEPHEN R. , CHENG YILING J. , GREGG EDWARD , ZHANG PING 
Published: June 2019

Increases in the number of new oral antidiabetic medications in the last decade have resulted in a change in payments. We examined the trends in total payment and patients’ out-of-pocket (OOP) payments on a yearly supply of various oral antidiabetic drug types from 2003 to 2016. We analyzed 1,803,427 adults with diabetes under fee for service plans from the 2003-2016 MarketScan commercial claims database. Antidiabetic drugs were grouped using National Drug Codes. Total and OOP payment for each drug type were modelled at a 30-day supply level, and later multiplied by 12 to obtain yearly estimates. Joinpoint regression was applied to identify the inflection point for trend changes and to estimate the magnitude of change in each defined segment. Payments were standardized to 2016 USD. Total payment for a yearly supply of newer drug types grew sharply after 2012, with an increasing rate of $334 (11%), $598 (10%), and $414 (11%) per year for DPP-4, GLP-1 and SGLT2, respectively (all p&lt; 0.01). For older drugs, a decrease in total payment for a yearly supply was observed among Sulfonylurea (-$9,-6%), Meglitinide (-$595,-34%), AGI (-$71.41, -10%) and TZD (-$721,-48%) per year after 2012 (all p &lt;0.01). Metformin is the only exception, which was found to have sharply increased at annual rate of $75 (32%, p&lt;0.01) for a yearly supply. Although total payment escalated over time, OOP payment on most drug types remained during the study periods (all p-values &gt;0.05). Only OOP payments on DPP-4, GLP-1, SGLT2 increased after 2010, but all below 5% per year and with p-values &gt;0.05. Patterns of changes in payment on a yearly supply of drugs varied by drug type. Payment on older drugs tended to decline with exception of an increase for Metfomin. Payment increases on newer oral drugs tended to accelerate over time. OPP payments also varied by drug types but mostly declined over time, implying that the increase in payment for the newer drugs was mainly borne by payers.

Disclosure
H. Shao: None. M. Laxy: None. S.R. Benoit: None. Y.J. Cheng: None. E. Gregg: None. P. Zhang: None.
124-LB: Patients’ Experiences with a Do-It-Yourself Artificial Pancreas and Perspectives of the Endocrinologist’s Role in Supporting Their Use
Authors: PALMER WALTER , GREELEY SIRI ATMA W. , LETOURNEAU LISA R. , NAYLOR ROCHELLE N. 
Published: June 2019

While commercial manufacturers push toward developing closed-loop insulin delivery systems, some type 1 diabetes patients are implementing self-built versions of such systems already. Use of these “do-it-yourself” (DIY) systems is increasing, but without standard regulatory oversight or clinical trial data.
The purpose of this study was to understand: 1) patients’ experiences with DIY systems and 2) their perspectives of how diabetes care providers have supported their use of such systems. We developed a survey through an iterative process and distributed via Twitter and Facebook to patients in the U.S. The survey was open for 2 weeks.
Respondents (n=101) were 2-72 years of age, from 34 states. A majority reported positive clinical outcomes, such as increased time in range (94%), less frequent sleep interruptions (93%), less frequent hyperglycemia (92%), less frequent hypoglycemia (89%), and lower HbA1c (74%).
Most respondents (89%) described DIY systems as “Safe” or “Very Safe,” whereas only 21% chose the same for traditional continuous glucose monitor and insulin pump combinations.
The majority of respondents were the only patient in their endocrinology practice on a DIY system (73%). Most reported their providers were “supportive” of their continued use (80%), but only 20% reported that their endocrinologist “understands the system well.”
Our results suggest that patients are adopting DIY systems with positive reported outcomes, and that endocrinologists are generally supportive despite limited experience with this technology. This study had limitations, including sample size, reliance on self-reported data, lack of a control group, and lack of data from endocrinology providers. Until commercially available closed-loop systems improve, the number of patients using DIY systems is likely to increase. Our research suggests that endocrinology providers may benefit from more exposure to such systems and education regarding their use.

Disclosure
W. Palmer: None. S.W. Greeley: None. L.R. Letourneau: None. R.N. Naylor: None.
1242-P: The Impact of Telehealth on the Management of Diabetes in Rural/Remote North Queensland, Australia: A Retrospective Cohort Study
Authors: NANGRANI NISHA , MALABU USMAN , VANGAVETI VENKAT 
Published: June 2019

Background: The prevalence of diabetes in rural and remote North Queensland is twice that of the general Australian population. The vast geographical distances in North Queensland prevent patients from accessing specialist diabetes care in tertiary hospitals. Telehealth (TH) presents a unique opportunity to overcome this barrier. However, the ability of TH to improve glycaemic control and vascular risk factors (blood pressure, body mass index, lipid profile) in comparison to traditional face-to-face (FTF) care in this population remains unknown.
Methods: This was a retrospective cohort study of all diabetes-related telehealth consultations conducted at the Townsville Hospital from January 2016 to March 2018. The primary outcome was the change in HbA1c post-FTF (face-to-face) care versus post-TH care. Secondary outcomes included change in blood pressure, body mass index and lipid profile. We conducted a preliminary economic analysis to determine patient cost-savings from the tele-diabetes model of care.
Results: 330 patients were included in the study. The majority (71%) had a diagnosis of type 2 diabetes. The median baseline HbA1c was 9.1% (8.0-10.8). HbA1c improved from 9.1% (post-FTF) to 8.1% post-TH intervention (z = -9.184, p&lt;0.001). We observed a reduction in total cholesterol levels (4.15 mmol/L to 4.00 mmol/L; z = -3.198, p&lt;0.001) and LDL-cholesterol (2.00 mmol/L to 1.80 mmol/L; z = -4.209, p&lt;0.001). The tele-diabetes model was associated with a total patient cost-savings of $131,710 (equating to $390 in cost-savings per patient per trip).
Conclusions: Telehealth consultations improved glycaemic control and lipid levels more effectively than traditional face-to-face care with significant cost savings for a rural and remote population in North Queensland, Australia.

Disclosure
N. Nangrani: None. U. Malabu: None. V. Vangaveti: None.
1245-P: The Association of Glucose Variability during the Last Day of Hospitalization and 30-Day Readmission in Adults with Diabetes
Authors: SPANAKIS ELIAS , SINGH LAKSHMI G. , SIDDIQUI TARIQ , SORKIN JOHN D. , NOTAS GEORGE , MAGEE MICHELLE F. , FINK JEFFREY C. , ZHAN MIN , UMPIERREZ GUILLERMO E. 
Published: June 2019

Objective: Thirty-day hospital readmission (30-day RA) rates are a metric of healthcare quality. Limited data is available, whether increased glucose variability (GV) during the last day of hospital stay is associated with an increased risk of 30-day RA.
Design: Nationwide cohort of 1,042,859 admissions of patients with diabetes in the non-critical care setting in 129 Veteran Affairs hospitals, between 2001-2014. Coefficient of Variation (CV) was measured using point of care- glucometer values and was used as measurement of GV, divided into ten equal categories (tentiles). Covariates, including demographics, socio-economic and hospital related factors and up to 30 comorbidities were collected. Poisson regression was used to determine if CV during the last stay day of the hospitalization was associated with 30-day RA.
Results: After adjusting for age, gender and race (Model 1), there was a gradual increase in 30-day RA ratio among admissions with higher CV. Following adjusting for all the covariates collected (Model 2), only admissions with the highest CV demonstrated an increased 30-day RA. The rate ratios and 95% CIs were 1.049 (1.026, 1.073, p&lt;0.0001), 1.038 (1.015,1.061, p=0.0011), 1.065 (1.042,1.089, p&lt;0.0001), for the 8th, 9th and the 10th tentiles respectively, compared to those with CV in the 1st tentile. In Model 3, after adjusting for covariates used in Model 2 and for hypoglycemia, results remained statistically significant for those admissions with the highest CV [rate ratios and 95% CIs are 1.044 (1.021,1.068, p=0.0001), 1.028 (1.006,1.052, p=0.014), 1.042 (1.018,1.067, p=0.0005) for the 8th, 9th and the 10th tentiles].
Conclusions: Higher glucose variability during the last day of hospitalization was associated with increased 30-day RA rates after adjustment for multiple covariates and hypoglycemia.

Disclosure
E. Spanakis: None. L.G. Singh: None. T. Siddiqui: None. J.D. Sorkin: None. G. Notas: None. M.F. Magee: Consultant; Self; Mytonomy. Research Support; Self; Lilly Diabetes, Mytonomy, Sanofi. Speaker's Bureau; Self; PRIMED. J.C. Fink: None. M. Zhan: None. G.E. Umpierrez: Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc. Research Support; Self; AstraZeneca, Merck & Co., Inc., Novo Nordisk Inc., Sanofi US.

Funding
U.S. Department of Veterans Affairs (1I01CX001825-01)
127-LB: Longevity of the Coated ConvaTec Infusion Set with Lantern Technology
Authors: LAL RAYHAN , SCHøNDORFF PERNELLE K. , HSU LIANA , HESCHEL MATTHIAS , BUCKINGHAM BRUCE A. 
Published: June 2019

Objective: Current insulin infusion sets are approved for 2-3 days of wear; however, glucose sensors are approved for 7-14 days of wear. A commonly reported reason for discontinuing use of CGM within 1 year is not wanting to wear devices on two sites of the body. Any attempt to create a combined glucose sensor and infusion set for closed-loop control requires a set with greater longevity. The coated ConvaTec Infusion Set with Lantern Technology is a new infusion set with multiple slits and coating intended to reduce foreign body response and occlusion from bending or kinking.
Methods: A pilot safety and extended wear tolerability study is being performed at Stanford University. To date, 15 adult subjects on tethered insulin pump therapy using insulin aspart or lispro have completed the study. Each participant places the set and wears it for 10 days or until set failure to establish a maximum length of infusion set wear when 80% of sets are still functional (excluding accidental “pull-outs”). Infusion set failures are based on: (1) Presence of serum ketones with hyperglycemia; (2) Unexplained hyperglycemia, unresolved with correction dose; (3) Signs of infection at the infusion site; (4) Pump occlusion alarm; and (5) Adhesive failure.
Results: Two subjects did not meet failure criteria and were excluded. Of the remaining, 6 (46%) wore the novel infusion set the full 10 days and all sets lasted 7 days or more (mean 8.8 days). 3 premature set failures were associated with persistent hyperglycemia unresponsive to correction boluses on days 7-8, 3 with adhesive failure on days 7-9, and 1 with infection on day 9.
Conclusions: In our previous studies assessing 353 infusion set insertions for 7 days, average length of wear was 5.1 ± 1.7 days. Thus far, the novel set has demonstrated increased longevity. The duration of wear established in this pilot study will be used to perform a masked, randomized controlled crossover study comparing the coated ConvaTec Infusion Set with Lantern Technology against standard infusion sets.

Disclosure
R. Lal: Consultant; Self; Abbott. P.K. Schøndorff: Employee; Self; ConvaTec Inc. L. Hsu: None. M. Heschel: Employee; Self; Unomedical a/s. B.A. Buckingham: Advisory Panel; Self; ConvaTec Inc., Novo Nordisk Inc., Profusa, Inc. Consultant; Self; Medtronic MiniMed, Inc. Research Support; Self; Beta Bionics, ConvaTec Inc., Dexcom, Inc., Insulet Corporation, Medtronic MiniMed, Inc., Tandem Diabetes Care. Other Relationship; Self; Insulet Corporation, Tandem Diabetes Care.